Detalles de la búsqueda
1.
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Lancet
; 389(10086): 2317-2327, 2017 06 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28551073
2.
Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2.
Rheumatology (Oxford)
; 57(11): 2001-2011, 2018 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30053162
Resultados
1 -
2
de 2
1
Próxima >
>>